Zoetis (ZTS) Other Non-Current Liabilities (2012 - 2026)
Zoetis (ZTS) posted quarterly Other Non-Current Liabilities of $281.0 million for Q1 2026, up 1.44% year-over-year from $277.0 million in Q1 2025, and up 12.4% quarter-over-quarter from $250.0 million in Q4 2025.
Zoetis (ZTS) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Other Non-Current Liabilities for 15 consecutive years, with $281.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 1.44% year-over-year to $281.0 million; the TTM figure through Mar 2026 stood at $281.0 million (up 1.44% YoY), while the FY2025 annual figure was $250.0 million, down 8.09% from the prior year.
- Other Non-Current Liabilities advanced to $281.0 million in Q1 2026 per ZTS's latest filing, from $250.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $281.0 million in Q1 2026 and bottomed at $216.0 million in Q1 2023.
- Historically, Other Non-Current Liabilities has averaged $249.5 million across 5 years, with a median of $250.0 million in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities retreated 10.73% — and 2025, when it grew 23.42%.
- Zoetis' Other Non-Current Liabilities stood at $258.0 million in 2022, then fell by 8.14% to $237.0 million in 2023, then advanced by 14.77% to $272.0 million in 2024, then decreased by 8.09% to $250.0 million in 2025, then increased by 12.4% to $281.0 million in 2026.
- Business Quant data shows ZTS's Other Non-Current Liabilities at $281.0 million in Q1 2026, $250.0 million in Q4 2025, and $264.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 288.00 Mn |
| Mar 31, 2026 | 281.00 Mn |
| Dec 31, 2025 | 250.00 Mn |
| Sep 30, 2025 | 264.00 Mn |
| Jun 30, 2025 | 274.00 Mn |
| Mar 31, 2025 | 277.00 Mn |
| Dec 31, 2024 | 272.00 Mn |
| Sep 30, 2024 | 274.00 Mn |
| Jun 30, 2024 | 222.00 Mn |
| Mar 31, 2024 | 228.00 Mn |
| Dec 31, 2023 | 237.00 Mn |
| Sep 30, 2023 | 259.00 Mn |
| Jun 30, 2023 | 217.00 Mn |
| Mar 31, 2023 | 216.00 Mn |
| Dec 31, 2022 | 258.00 Mn |
| Sep 30, 2022 | 239.00 Mn |
| Jun 30, 2022 | 233.00 Mn |
| Mar 31, 2022 | 241.00 Mn |
| Dec 31, 2021 | 239.00 Mn |
| Sep 30, 2021 | 251.00 Mn |